ViatrisHAM:VIA -1.15%60 Days Payable is 47.89 as of Mar. 2026, which is 7% below its 10-year median of 51.56. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.58 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 920 Drug Manufacturers companies, Viatris ranks worse than 74.67% on this metric.
Viatris's average Accounts Payable for the
three
months ended in Mar. 2026 was €1,071 Mil. Viatris's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €2,041 Mil.
Hence, Viatris's Days Payable for the
three
months ended in Mar. 2026 was 47.89.
The historical rank and industry rank for Viatris's Days Payable or its related term are showing as below:
HAM:VIA'
s Days Payable Range Over the Past 10 Years
Min: 35.61 Med: 51.56 Max: 54.79
Current: 50.88
During the past 13 years, Viatris's highest Days Payable was 54.79. The lowest was 35.61. And the median was 51.56.
HAM:VIA's Days Payable is ranked worse than 74.67% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs HAM:VIA: 50.88
Viatris's Days Payable
declined
from Mar. 2025 (63.59) to Mar. 2026 (47.89).
It may suggest that Viatrisaccelerated paying its suppliers.
Viatris Days Payable Related Terms
Viatris Days Payable Historical Data
* Premium members only.
The historical data trend for Viatris's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Days Payable distribution charts can be found below:
* The bar in red indicates where Viatris's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Viatris's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a Days Payable of 47.89 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Viatris and its competitors. This is near median its historical median of 51.56. Over the past decade, Viatris' Days Payable has ranged from 35.61 to 54.79. According to the industry distribution chart, Viatris ranks #687 out of 920 companies in the Drug Manufacturers industry, placing it in the top 74.7%.
Is Viatris' Days Payable too high?
Viatris' current Days Payable of 47.89 is near median its 10-year median of 51.56. Over the past 10 years, this metric has ranged from a low of 35.61 to a high of 54.79. The Drug Manufacturers industry median Days Payable is 90.84. Viatris' value of 47.89 is 47.3% below this industry median. Based on the distribution chart, Viatris ranks #687 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Days Payable compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #687 out of 920 companies for Days Payable. This places Viatris in the lower half of its industry. The industry median Days Payable is 90.84. Viatris' value of 47.89 is 47.3% below this benchmark. Historically, Viatris' own Days Payable has ranged from 35.61 to 54.79 over the past decade. While the company's 10-year median is 51.56 vs. the industry median of 90.84, Viatris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current Days Payable of 47.89 is 47.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current Days Payable is 47.89, which is near median its own 10-year median of 51.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.58, compared to a current price of €14.10 — trading 47.2% above its estimated fair value. The current Days Payable is 47.89, which is near median its 10-year median of 51.56 and 47.3% below the Drug Manufacturers industry median of 90.84. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Days Payable is 47.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.10 is trading 47.2% above its estimated GF Value™ of €9.58.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
Days Payable: 47.89 (near median its 10-year median of 51.56)
GF Value™: €9.58 vs. price of €14.10 (47.2% above fair value)
Industry Position: 47.3% below the Drug Manufacturers median (#687 of 920)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for HAM:VIA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
